Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients

Journal of Hypertension

Volumn 34, Issue 2, 2016, Pages 345-350

  Forst, Thomas ^a,b   Michelson, Georg ^c   Diessel, Stephan ^a   Jahnke, Johannes ^a   Kapitza, Christoph ^d  

^a Profil Mainz   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Profil Institute for Metabolic Research   (Germany)

Author keywords

Dipeptidylpeptidase IV inhibition; Hypertension; Renal function; Retinal microvascular blood flow; Transforming growth factor beta

Indexed keywords

C REACTIVE PROTEIN; CYCLIC GUANOSINMONOPHOSPHATE; CYSTATIN C; HEMOGLOBIN A1C; LINAGLIPTIN; N(G),N(G) DIMETHYLARGININE; PHOSPHATE; PLACEBO; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ARGININE; CYCLIC GMP; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; N,N-DIMETHYLARGININE;

ADULT; AGED; ARTERIAL PRESSURE; ARTERY BLOOD FLOW; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CARDIAC PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; HUMAN; HYPERTENSION; LASER DOPPLER FLOWMETRY; MALE; MICROCIRCULATION; MICROVASCULARIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA BLOOD FLOW; RETINA CAPILLARY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; BLOOD FLOW; DRUG EFFECTS; METABOLISM; MICROVASCULATURE; MIDDLE AGED; PATHOPHYSIOLOGY; RETINA BLOOD VESSEL;

AGED; ARGININE; ARTERIAL PRESSURE; C-REACTIVE PROTEIN; CYCLIC GMP; CYSTATIN C; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; LINAGLIPTIN; MALE; MICROVESSELS; MIDDLE AGED; REGIONAL BLOOD FLOW; RETINAL VESSELS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84957441808     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000776     Document Type: Article

References (37)

1. He BB, Wei L, Gu YJ, Han JF, Li M, Liu YX, et al. Factors associated with diabetic retinopathy in chinese patients with type 2 diabetes mellitus. Int J Endocrinol 2012; 2012:157940.
2. Sabanayagam C, Shankar A, Koh D, Chia KS, Saw SM, Lim SC, et al. Retinal microvascular caliber and chronic kidney disease in an Asian population. Am J Epidemiol 2009; 169:625-632.
3. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res 2012; 9:109-116.
4. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocininduced diabetic rats. J Pharmacol Exp Ther 2012; 340:248-255.
5. Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011; 223:133-135.
6. Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BP, Lessa LM, Malnic G, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 2011; 301:F355-F363.
7. Betteridge DJ, Verges B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Int J Obes Relat Metab Disord 2005; 48:2477-2481.
8. van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011; 34:2072-2077.
9. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33:187-215.
10. Groop PH, Cooper M, Perkovic V, Emser A, von EM, Woerle HJ. Linagliptin lowers albuminuria on top of recommended standard treatment for diabetic nephropathy. Diabetes 2012; 61 (Suppl 1):A243.
11. Berndt-Zipfel C, Michelson G, Dworak M, Mitry M, Loffler A, Pfutzner A, et al. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus: results from an exploratory study. Cardiovasc Diabetol 2013; 12:59.
12. Kreis AJ, Nguyen T, Rogers S, Wang JJ, Harazny J, Michelson G, et al. Reliability of different image analysis methods for scanning laser Doppler flowmetry. Curr Eye Res 2008; 33:493-499.
13. Michelson G, Welzenbach J, Pal I, Harazny J. Functional imaging of the retinal microvasculature by scanning laser Doppler flowmetry. Int Ophthalmol 2001; 23:327-335.
14. Michelson G, Welzenbach J, Pal I, Harazny J. Automatic full field analysis of perfusion images gained by scanning laser Doppler flowmetry. Br J Ophthalmol 1998; 82:1294-1300.
15. Garhofer G, Zawinka C, Resch H, Kothy P, Schmetterer L, Dorner GT. Reduced response of retinal vessel diameters to flicker stimulation in patients with diabetes. Br J Ophthalmol 2004; 88:887-891.
16. Mandecka A, Dawczynski J, Blum M, Muller N, Kloos C, Wolf G, et al. Influence of flickering light on the retinal vessels in diabetic patients. Diabetes Care 2007; 30:3048-3052.
17. Nagel E, Vilser W, Lanzl I. Age, blood pressure, and vessel diameter as factors influencing the arterial retinal flicker response. Invest Ophthalmol Vis Sci 2004; 45:1486-1492.
18. Delles C, Michelson G, Harazny J, Oehmer S, Hilgers KF, Schmieder RE. Impaired endothelial function of the retinal vasculature in hypertensive patients. Stroke 2004; 35:1289-1293.
19. Maeda S, Yamagishi S, Matsui T, Nakashima S, Ojima A, Maeda S, et al. Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats. Ophthalmic Res 2013; 50:221-226.
20. Goncalves A, Leal E, Paiva A, Teixeira LE, Teixeira F, Ribeiro CF, et al. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes Obes Metab 2012; 14:454-463.
21. Goncalves A, Marques C, Leal E, Ribeiro CF, Reis F, Ambrosio AF, et al. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochim Biophys Acta 2014; 1842:1454-1463.
22. Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010; 9:6.
23. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010; 23:334-339.
24. Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, et al. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 2012; 61:888-896.
25. Abd El Motteleb DM, Elshazly SM. Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor. Eur J Pharmacol 2013; 720:158-165.
26. Dai Y, Mehta JL, Chen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther 2013; 27:371-380.
27. Aroor AR, Sowers JR, Bender SB, Nistala R, Garro M, Mugerfeld I, et al. Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology 2013; 154:2501-2513.
28. Shah Z, Pineda C, Kampfrath T, Maiseyeu A, Ying Z, Racoma I, et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 2011; 55:2-9.
29. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48:592-598.
30. Hendarto H, Inoguchi T, Maeda Y, Ikeda N, Zheng J, Takei R, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase Amediated inhibition of renal NAD(P)H oxidases. Metabolism 2012; 61:1422-1434.
31. Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, et al. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem Biophys Res Commun 2014; 443:828-833.
32. Gao H, Xu L, Li D, Guang L, Deng W. Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-alpha and TGF-beta1 in rats with nonalcoholic fatty liver disease. Nan Fang Yi Ke Da Xue Xue Bao 2013; 33:1661-1664.
33. Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 2014; 63:2120-2131.
34. Zorena K, Malinowska E, Raczynska D, Mysliwiec M, Raczynska K. Serum concentrations of transforming growth factor-beta 1 in predicting the occurrence of diabetic retinopathy in juvenile patients with type 1 diabetes mellitus. J Diabetes Res 2013; 2013:614908.
35. Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2006; 2:71-98.
36. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med (Berl) 1995; 73:333-346.
37. Nunes I, Munger J, Harpel JG, Nagano Y, Shapiro R, Gleizes PE, et al. Structure and activation of the large latent transforming growth factorbeta complex. J Am Optom Assoc 1998; 69:643-648.